Souhaitez-vous accéder aux communiqués récents ?

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025Glasgow, Scotland – 28 April 2025. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company...

Dublin, March 21, 2025 (GLOBE NEWSWIRE) -- The "Microbiome Disease - Pipeline Insight, 2025" drug pipeline report has been added to ResearchAndMarkets.com's offering.The report provides...

EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS) EBX-102-02 demonstrated clinically meaningful...

Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Microbiome Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. This report contains a...

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...

Biongevity launches UAE’s top longevity plans after a record-breaking fitness challenge, integrating AI, genomics, and precision medicine for Healthspan.

US & Canada, Feb. 06, 2025 (GLOBE NEWSWIRE) -- According to a comprehensive report from The Insight Partners, “Human Microbiome Market Size and Forecast (2021 - 2031), Global and Regional Share,...

BioAro launches PanOmiQ, the world's fastest AI-driven WGS platform, delivering real-time genomic insights in under 2 hours for precision medicine.

Persephone Biosciences Announces Full Enrollment in AMBROSIA Food as Medicine Study

Persephone Biosciences Announces First Subject Enrolled in ARTEMIS Clinical Trial of New Infant Synbiotic